期刊文献+

伊马替尼与干扰素联合羟基脲对慢性粒细胞白血病的疗效

The Curative Effect of Imatinib and Interferon Combined With Hydroxyurea for Chronic Myelogenous Leukemia
下载PDF
导出
摘要 目的研究分析伊马替尼与干扰素联合羟基脲治疗慢性粒细胞白血病的疗效。方法选取我院收治的慢性粒细胞白血病患者68例作为研究对象。将患者随机分为观察组与对照组。观察组患者给予伊马替尼治疗,对照组患者给予干扰素联合羟基脲治疗。观察并比较两组患者的应用效果情况。结果治疗后,两组患者的血液学疗效比较,差异无统计学意义(P>0.05)。观察组患者细胞遗传学疗效优于对照组患者,差异具有统计学意义(P<0.05)。结论伊马替尼与干扰素联合羟基脲治疗慢性粒细胞白血病的临床疗效均较为确切,但伊马替尼在细胞遗传学方面疗效更加确切。 Objective To study the curative effect of imatinib and interferon combined with hydroxyurea for chronic myelogenous leukemia. Methods 68 cases of patients with chronic myelogenous leukemia in our hospital were selected as the study objects and they were randomly divided into observation group and control group. The observation group was treated with imatinib, the control group was treated with hydroxyurea combined with interferon. The application effect between two groups was compared. Results There was no significant difference in hematological efficacy between the two groups after treatment(P 0.05). The cytogenetic curative effect of the observation group was significantly better than that of the control group, the difference was statistically significant(P0.05). Conclusion The clinical efficacy of imatinib and interferon combined with hydroxyurea for chronic myelogenous leukemia are both precise, but the effect of imatinib on cell genetics is more exact.
作者 张冬霞 云雁
出处 《中国继续医学教育》 2017年第32期90-91,共2页 China Continuing Medical Education
关键词 伊马替尼 干扰素 羟基脲 白血病 疗效 imatinib interferon hydroxyurea leukemia curative effect
  • 相关文献

参考文献9

二级参考文献106

  • 1中华医学会血液学分会.中国慢性髓性白血病诊断与治疗指南(2013年版)[J].实用器官移植电子杂志,2013,1(6). 被引量:7
  • 2张之楠,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:271-271.
  • 3Cortes J.Natural history and staging of chronic myelogenous leukemia.Hematol Oncol Clin North Am,2004,18(3):569-84,viii.
  • 4Interferon alfa versus chemotherapy for chronic myeloid leukemia:a metaanalysis of seven randomized trials:Chronic Myeloid Leukemia Trialists' Collaborative Group.J Natl Cancer Inst,1997,89(21):1616-1620.
  • 5Guilhot F,Chastang C,Michallet M,et al.Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia.N Engl J Med,1997,337(4):223-229.
  • 6Cohen MH,Williams G,Johnson JR,et al.Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.Clin Cancer Res,2002,8(5):935-942.
  • 7O'Brien SG,Guilhot F,Larson RA,et al.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med,2003,348(11):994-1004.
  • 8An X,Tiwari AK,Sun Y,et al.BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia:a review.Leuk Res,2010,34(10):1255-1268.
  • 9Soverini S,Colarossi S,Gnani A,et al.Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients:by the G1MEMA Working Party on Chronic Myeloid Leukemia.Clin Cance Res.2006,12(24):7374-7379.
  • 10O'Brien S,Berman E,Borghaei H,et al.NCCN clinical practice guidelines in oncology:chronic myelogenous leukemia.J Natl Compr Cane Netw,2009,7(9):984-1023.

共引文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部